The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Drug Target Review

SEPTEMBER 8, 2023

” Several years ago, Cheroutre and her colleagues released research findings demonstrating that retinoic acid (RA), derived from vitamin A, triggers the activation of nuclear RARα and fosters gene expression that is critical for the differentiation of regulatory T cells with suppressive abilities, ultimately dampening immune responses.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

JUNE 25, 2021

“These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Variant Virus Strains. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing. against the original virus strain, 86.3%

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

DECEMBER 28, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. . HOUSTON , Dec. 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc.,

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

JANUARY 22, 2021

They also have the potential to be self-administered, reducing health systems’ dependency on trained health professionals to run immunization programs and present a future where people could have vaccines delivered straight to their door.”.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

JANUARY 31, 2021

Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

OCTOBER 20, 2020

Research sponsored by Moleculin and recently presented at the American Association of Cancer Research (AACR) Annual Meeting held from June 22nd-24th, 2020 suggested a possible reason for this limited efficacy may be the inability of doxorubicin to sufficiently accumulate in the lungs in concentrations required to kill tumor cells.

Pharmaceutical Companies 40

Pharmaceutical Companies Clinical Trials Treatment Virus 40

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

SEPTEMBER 5, 2021

” These findings were presented at the European Respiratory Society (ERS) International Congress 2021 between September 5-8. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

NOVEMBER 9, 2020

Results from the NAVIGATOR trial will be presented at an upcoming medical meeting. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Type 2 inflammation in asthma–present in most, absent in many. J Allergy Clin Immunol.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 21, 2020

Detailed results from the SOURCE trial will be presented at a future medical meeting. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Further analyses of the data are ongoing.

Trials 40

Trials Production Clinical Trials Therapies 40

DrugBank

JULY 18, 2024

These epitopes serve as the primary targets for the immune system, triggering a response that protects against future infection. For instance, the influenza virus is notorious for its ability to undergo antigenic drift, accumulating mutations in its surface proteins that can render existing vaccines less effective. 

Vaccine 99

Vaccine Immune Response Clinical Trials Virus 99

DrugBaron

APRIL 13, 2020

More than a month after the World Health Organisation declared COVID19 a global pandemic on 11th March we are still missing one crucial piece of data from our modelling: the fraction of people who have established productive immunity against the SARS-CoV2 virus.

Immune Response 100

Immune Response Virus Vaccine Production 100

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens.

Engineering 110

Engineering DNA Virus Medical Schools 110

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 137

Therapies Virus DNA Clinical Trials 137

Drug Target Review

OCTOBER 2, 2024

While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.

Therapies 98

Therapies Disease RNA Engineering 98

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

DECEMBER 16, 2020

Throughout the day, various presentations will be given by medical experts pertaining to Emergency Use Authorization (EUA). The technology leveraged to create the vaccine does not require the actual virus, according to CNN. Instead, it uses a genetic code, which tricks the body into developing an immune response to the virus.

Vaccine 52

Vaccine Immune Response FDA Virus 52

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Immune Response 52

Immune Response Virus Disease Doctors 52

Drug Target Review

JULY 11, 2023

In simple terms, our immune system is divided into innate and adaptive responses – the innate being the first line of defence, and the adaptive responds to specific challenges by modifying the body’s immune response in a tailored fashion. B-cell white blood cell, type of lymphocyte produce antibody molecules.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. Regulatory submissions for TAK-003 include long-term safety and efficacy data through 36 months from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.

Vaccine 52

Vaccine Virus Trials Hospitals 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Most people would take the two CRISPR gene-editing components (a Cas9 protein and guide RNA), package them up inside of a virus, and then inject the viruses into the skulls of mice. Please send me your feedback.

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

This newsletter’s format has shifted again, as I try to figure out the most enticing way to present this stuff. Most people would take the two CRISPR gene-editing components (a Cas9 protein and guide RNA), package them up inside of a virus, and then inject the viruses into the skulls of mice. Please send me your feedback.

Vaccine 52

Vaccine DNA Virus Engineering 52

Agency IQ

MARCH 7, 2024

BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.

Vaccine 40

Vaccine FDA Virus Licensing 40

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JULY 8, 2021

Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.(24,25). Nat Rev Immunol.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Like other members of this genus, SARS-CoV-2 is equipped with several molecular tools that allow it to evade recognition by the immune system.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

JANUARY 5, 2021

Slaoui said earlier data showed that the vaccine appeared to rouse similar antibody responses among volunteers under age 55 who received either the full 100-microgram dose or a half dose. But a faster-spreading virus could swamp hospitals with seriously ill patients. ” Changing the dosage could also hamper the U.S. In the U.K.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

NOVEMBER 29, 2020

The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at [link]. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Drug Target Review

JANUARY 3, 2024

Nanobodies are a novel and unique class of antigen-binding fragments, derived from naturally occurring heavy-chain-only antibodies present in the serum of camelids. This is because this blocks the transmission chain, preventing the virus from spreading from cell to cell. Viruses in the GII.4 4 norovirus.

Virus 65

Virus Immune Response Vaccine Disease 65

The Pharma Data

JANUARY 29, 2021

Multi-continent Study Provides Clinical Data on Multiple Emerging Viral Mutations The ENSEMBLE study results include efficacy against newly emerging strains of coronavirus, including some highly infectious variants present in the US, Latin America and South Africa. Global Head, Janssen Research & Development. i] [link] [ii] The B.1.351

Vaccine 40

Vaccine Trials Pharmaceutical Companies Clinical Trials 40

Codon

JULY 27, 2023

“The first printout of the human genome to be presented as a series of books, displayed in the 'Medicine Now' room at the Wellcome Collection, London. a lower risk of immune responses. Here are just a few: About 30,000 people know how to synthesize an influenza virus, at a cost of about $5,000.

Therapies 52

Therapies RNA DNA Engineering 52